PL3171174T3 - Laktoferryna do zastosowania w diagnostyce lub prognozowaniu choroby Alzheimera - Google Patents

Laktoferryna do zastosowania w diagnostyce lub prognozowaniu choroby Alzheimera

Info

Publication number
PL3171174T3
PL3171174T3 PL15195662T PL15195662T PL3171174T3 PL 3171174 T3 PL3171174 T3 PL 3171174T3 PL 15195662 T PL15195662 T PL 15195662T PL 15195662 T PL15195662 T PL 15195662T PL 3171174 T3 PL3171174 T3 PL 3171174T3
Authority
PL
Poland
Prior art keywords
lactoferrin
prognosis
alzheimer
diagnosis
disease
Prior art date
Application number
PL15195662T
Other languages
English (en)
Inventor
Eva María CARRO DÍAZ
Original Assignee
Geroa Diagnostics, S.L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geroa Diagnostics, S.L filed Critical Geroa Diagnostics, S.L
Publication of PL3171174T3 publication Critical patent/PL3171174T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79Transferrins, e.g. lactoferrins, ovotransferrins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15195662T 2015-11-20 2015-11-20 Laktoferryna do zastosowania w diagnostyce lub prognozowaniu choroby Alzheimera PL3171174T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15195662.0A EP3171174B1 (en) 2015-11-20 2015-11-20 Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease

Publications (1)

Publication Number Publication Date
PL3171174T3 true PL3171174T3 (pl) 2018-04-30

Family

ID=54697475

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15195662T PL3171174T3 (pl) 2015-11-20 2015-11-20 Laktoferryna do zastosowania w diagnostyce lub prognozowaniu choroby Alzheimera
PL16809652T PL3377909T3 (pl) 2015-11-20 2016-11-17 Laktoferyna do zastosowania w diagnozowaniu lub prognozowaniu choroby Alzheimera

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16809652T PL3377909T3 (pl) 2015-11-20 2016-11-17 Laktoferyna do zastosowania w diagnozowaniu lub prognozowaniu choroby Alzheimera

Country Status (28)

Country Link
US (2) US11422137B2 (pl)
EP (2) EP3171174B1 (pl)
JP (1) JP6991970B2 (pl)
KR (1) KR102579727B1 (pl)
CN (1) CN108431608B (pl)
AU (1) AU2016354981B2 (pl)
BR (1) BR112018010266A2 (pl)
CA (1) CA3005784C (pl)
CL (1) CL2018001343A1 (pl)
CO (1) CO2018006298A2 (pl)
CY (1) CY1119797T1 (pl)
DK (1) DK3171174T3 (pl)
EC (1) ECSP18046355A (pl)
ES (1) ES2657414T3 (pl)
HR (1) HRP20180115T1 (pl)
HU (1) HUE037916T2 (pl)
LT (1) LT3171174T (pl)
MD (1) MD3171174T2 (pl)
ME (1) ME02993B (pl)
MX (1) MX2018006189A (pl)
NO (1) NO3171174T3 (pl)
PL (2) PL3171174T3 (pl)
PT (1) PT3171174T (pl)
RS (1) RS56832B1 (pl)
RU (1) RU2745602C2 (pl)
SI (1) SI3171174T1 (pl)
WO (1) WO2017085214A1 (pl)
ZA (1) ZA201804079B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201818373A2 (tr) 2018-12-03 2020-06-22 T C Erciyes Ueniversitesi Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇
CN112142850A (zh) * 2019-06-27 2020-12-29 深圳市卫光生物制品股份有限公司 人神经生长因子-乳铁蛋白重组蛋白及用途
CN111415745A (zh) * 2020-04-03 2020-07-14 河北医科大学 一种雄激素提示老年男性阿尔茨海默病风险的计算方法
CN113049696B (zh) * 2021-03-04 2022-03-18 首都医科大学宣武医院 一种诊断受试者是否患阿尔茨海默病的代谢产物及其用途
CN113967250A (zh) * 2021-09-26 2022-01-25 四川大学 乳铁蛋白在预防治疗阿尔兹海默症中的应用
CN114242175A (zh) * 2021-12-22 2022-03-25 香港中文大学深圳研究院 一种评估脑白质高信号体积的方法及系统
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US7192724B2 (en) * 2000-11-14 2007-03-20 Techlab, Inc. Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker
US20030096736A1 (en) 2001-05-09 2003-05-22 Kruzel Marian L. Lactoferrin for age related disorders in humans
CA2502976C (en) * 2002-10-25 2012-05-22 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
WO2009074331A2 (en) 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
EP2389289A4 (en) * 2009-01-23 2012-11-07 Univ Drexel APPARATUS AND METHODS FOR DETECTING INFLAMMATION USING QUANTUM POINTS
EP2251032A1 (en) 2009-05-12 2010-11-17 Nestec S.A. Lactoferrin and brain health and protection in adults
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
US20110236917A1 (en) 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
RU2563987C2 (ru) * 2010-10-20 2015-09-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для болезни альцгеймера или умеренного когнитивного расстройства
EP2734543B1 (en) * 2011-07-24 2018-10-03 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
CA2877975C (en) 2012-04-13 2021-09-21 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
CN103575903B (zh) * 2012-08-07 2016-01-20 中国检验检疫科学研究院 一种人乳铁蛋白夹心elisa检测试剂盒及其应用

Also Published As

Publication number Publication date
AU2016354981A2 (en) 2018-08-09
RU2018122111A (ru) 2019-12-20
CY1119797T1 (el) 2018-06-27
RU2745602C2 (ru) 2021-03-29
ECSP18046355A (es) 2018-09-30
HRP20180115T1 (hr) 2018-04-06
US20180328949A1 (en) 2018-11-15
JP6991970B2 (ja) 2022-01-13
EP3377909A1 (en) 2018-09-26
EP3377909B1 (en) 2020-07-22
RU2018122111A3 (pl) 2019-12-20
US11422137B2 (en) 2022-08-23
BR112018010266A2 (pt) 2019-02-05
MX2018006189A (es) 2018-09-21
JP2018536410A (ja) 2018-12-13
HUE037916T2 (hu) 2018-09-28
PL3377909T3 (pl) 2021-04-06
MD3171174T2 (ro) 2018-02-28
CN108431608B (zh) 2021-12-07
KR102579727B1 (ko) 2023-09-19
WO2017085214A1 (en) 2017-05-26
CA3005784C (en) 2023-06-13
PT3171174T (pt) 2018-01-12
NO3171174T3 (pl) 2018-03-24
AU2016354981A1 (en) 2018-07-05
ZA201804079B (en) 2019-09-25
CN108431608A (zh) 2018-08-21
AU2016354981B2 (en) 2022-06-16
SI3171174T1 (en) 2018-04-30
CL2018001343A1 (es) 2018-12-21
RS56832B1 (sr) 2018-04-30
EP3171174A1 (en) 2017-05-24
CO2018006298A2 (es) 2018-09-20
EP3171174B1 (en) 2017-10-25
ES2657414T3 (es) 2018-03-05
LT3171174T (lt) 2018-02-12
KR20180083909A (ko) 2018-07-23
CA3005784A1 (en) 2017-05-26
ME02993B (me) 2018-10-20
DK3171174T3 (en) 2018-01-22
US20230081393A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
PL3377909T3 (pl) Laktoferyna do zastosowania w diagnozowaniu lub prognozowaniu choroby Alzheimera
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer's disease
EP3577455A4 (en) BIOMARKERS FOR THE DIAGNOSIS AND CHARACTERIZATION OF ALZHEIMER'S DISEASE
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
RS64744B1 (sr) Jedinjenja za upotrebu u lečenju alchajmerove bolesti kod pacijenata sa apoe4+/+
IL263188B (en) Treatment for Parkinson's disease
GB201512596D0 (en) Biomolecules involved in Alzheimer's disease
IL264040A (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
HK1243709A1 (zh) 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
PL3449009T3 (pl) Biomarkery mikroRNA we krwi do diagnozowania choroby Alzheimera
ZA201807944B (en) Treatment for parkinson's disease
IL256880A (en) Combining proteins for the diagnosis of schizophrenia
GB201614863D0 (en) Alzheimer's disease
GB201610205D0 (en) Therapies for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201414038D0 (en) Alzheimer's disease
GB201510067D0 (en) Polymorphisms associated with alzheimer's disease
EP3145531A4 (en) Ceacam5 peptides for crohn's disease